Professional Documents
Culture Documents
www.elsevier.com/locate/jns
Abstract
Objectives: Beta-blockers reduce mortality in patients after myocardial infarction. Experimental studies suggest that beta-blockers have also
neuroprotective properties. The aim of this study was to assess if use of beta-blockers is associated with reduced risk of early death in
ischemic stroke patients.
Materials and methods: Retrospective data analysis of 841 consecutive patients with acute ischemic stroke admitted to the stroke unit within
24 h after stroke onset.
Results: 10.6% of patients received beta-blockers during hospitalization. Thirty-day case fatality was significantly lower in patients treated
with beta-blockers than in those not treated with beta-blockers (6.8% versus 19.0%, Pb0.01). After adjustment for other prognostic factors,
the use of beta-blockers was associated with reduced risk of early death (relative hazard 0.37, 95% confidence interval 0.160.84)
independently of age, stroke severity, fasting glucose, total cholesterol level and pneumonia. When patients who died of cardiovascular
causes were excluded from the analysis, the use of beta-blocker was no longer significantly associated with risk of death (P = 0.12).
Conclusion: In a retrospective series the use of beta-blockers was associated with reduced risk of early death in patients with ischemic stroke.
2006 Elsevier B.V. All rights reserved.
Keywords: Beta-blockers; Cerebral infarction; Mortality; Stroke
1. Introduction
Corresponding author. Tel.: +48 12 424 86 00; fax: +48 12 424 86 26.
E-mail address: Dziedzic@cm-uj.krakow.pl (T. Dziedzic).
0022-510X/$ - see front matter 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.jns.2006.10.007
54
Table 1
Characteristics of stroke patients treated with beta-blockers and those not
treated with beta-blockers
Patients treated
Patients not treated
with beta-blockers with beta-blockers
(N = 88)
(N = 745)
67.2 (12.1)
39 (44.3)
72 (81.8)
13 (14.8)
61 (69.3)
69.9 (12.7)
350 (47.0)
494 (66.3)
162 (21.7)
427 (57.3)
0.03
0.64
b0.01
0.12
0.03
22 (25.0)
87 (11.7)
b0.01
25 (28.4)
21 (23.9)
10 (11.4)
4 (4.5)
6.0 (2.5)
149 (20.0)
196 (26.3)
60 (8.0%)
85 (11.4)
6.4 (2.4)
0.08
0.62
0.30
0.05
0.06
5.4 (1.7)
1.5 (1.1)
5.4 (1.3)
1.5 (1.2)
0.85
0.67
3.4 (1.1)
3.4 (1.1)
0.92
1.3 (0.3)
1.4 (0.5)
0.52
36.0 (23.043.5)
34.0 (20.043.0)
0.32
162 (33)
161 (29)
0.64
95 (18)
94 (16)
0.39
17 (19.3)
47 (53.4)
15 (17.0)
9 (10.2)
0 (0)
53 (60.2)
17 (19.3)
6 (6.8)
108 (14.5)
394 (52.9)
145 (19.5)
94 (12.6)
4 (0.5)
255 (34.2)
56 (7.5)
141 (18.9)
4
0
2
0
56
2
82
1
0.68
b0.01
b0.01
b0.01
0.30
0.01
ACE: angiotensin converting enzyme; TIA: transient ischemic attack; TC: total
cholesterol; TG: triglycerides; LDL: low density lipoproteins cholesterol;
HDL: high density lipoproteins cholesterol; SSS: Scandinavian Stroke Scale;
TACI: total anterior circulation infarction; PACI: partial anterior circulation
infarction; POCI: posterior circulation infarction; LACI: lacunar infarction.
a
Unfractionated intravenous heparin and low-molecular-weight heparins.
3. Results
In years 19941997 we hospitalized 841 patients with
ischemic stroke admitted to our stroke unit within 24 h after
stroke onset. Eight patients had inadequate data for analysis
because of immediate death. Thus, complete data were
available for 833 patients (mean age: 69.6 12.6; 46.7% men).
Eighty eight from 833 (10.6%) patients received betablockers during hospitalization. 94.3% of them were treated
with beta-blocker before admission. These patients continued therapy with beta-blockers during acute phase of stroke.
The patients treated with beta-blockers were significantly
younger and more often suffered from hypertension and
ischemic heart disease and had history of myocardial
infarction than those who did not receive beta-blockers.
The characteristics of both group are shown in Table 1.
30-Day case fatality was significantly lower in patients
receiving beta-blockers than in those who did not receive
beta-blockers (6.8% versus 19.0%, P b 0.01). Fig. 1 shows
the KaplanMeier cumulative survival curves for patients
treated and those not treated with beta-blockers. The use of
beta-blockers was associated with reduced risk of death
caused by cardiovascular events (myocardial infarction,
heart failure, or sudden death) (2.3% of 88 patients versus
11.0% of 745 patients, P = 0.01).
On univariate analysis the following variables were
significantly associated with risk of early death: age (OR:
1.04 per 1 year increase, 95% CI: 1.021.06), ischemic heart
disease (OR: 1.97, 95% CI: 1.332.91), atrial fibrillation
55
56